The invention discloses a linear or substantially linear epitope on netrin-1 that likely corresponds to the specific binding region of netrin-1 to receptor, in particular of the UNC5 class, especially UNC5B and UNC5A, or alternatively corresponds to a region nearby the specific binding region of netrin-1 to receptor that when bound to an antibody prevents netrin-1/receptor interaction. This determination of a linear epitope allows the Applicant to produce antibodies binding to netrin-1 and interfering with netrin-1/receptor interaction, thereby inducing apoptosis or cell death of tumour cells expressing or overexpressing netrin-1 and at least one netrin-1 receptor, owing the fact that this interaction inhibits netrin-1 binding to a receptor and the multimerization of the receptor. The invention discloses a murine monoclonal antibody directed against this epitope and various humanized forms thereof.本發明揭示一種軸突導向因子-1上之線性或實質上線性抗原決定基，其可能對應軸突導向因子-1對受體(特別是UNC5類，尤其UNC5B及UNC5A)之特異性結合區域或者對應軸突導向因子-1對受體之特異性結合區域鄰近之區域，當結合至抗體時，防止軸突導向因子-1/受體相互作用。此線性抗原決定基之確定容許申請人生產結合至軸突導向因子-1並干擾軸突導向因子-1/受體相互作用之抗體，從而誘導表現或過度表現軸突導向因子-1及至少一種軸突導向因子-1受體之腫瘤細胞之凋亡或細胞死亡，因為此相互作用抑制軸突導向因子-1結合至受體並抑制該受體之多聚化之事實。本發明揭示一種針對此抗原決定基之鼠科單株抗體及其各種人類化形式。
